Starbreeze’s third-quarter results came in below expectations, with Payday 3 sales underperforming w...
Redeye comments on Moberg Pharma’s Q3 report, in which sales came in slightly ahead of our forecast ...
Redeye is bullish after the strong numbers from the NeoLIPA readout presented this morning.
Redeye provides an update following Scibase’s Q3 report and intensive news flow last Friday.
Redeye comments on EG7’s Q3-results which were close to our expectations, albeit with somewhat softe...
Redeye initiates coverage of VEF, a specialised investment company that offers rare public market ac...
Tallinna Sadam's net sales and adjusted EBIT were relatively close to our expectations for Q3.
Investors House's Q3 report was the first since the divestment of the Apitare JV, of which Investors...
Redeye provides a brief comment on Verrica's new results from the study in BCC.
Redeye comments on qbeyond’s Q3 report showing softer underlying figures than we expected.
Group net sales was EUR 31.7m in Q3 (Nordea estimate EUR 32.
Redeye sees the phase I results from the controlled study of semaglutide monthly depot as a success,...
Investors House reported Q3 revenues of EUR 1.4m, in line with our estimate.
Redeye returns with an update following Ascelia Pharma's Q3 update, which contained no surprises.
* Q3: flat org. sales growth, SEK 12m adj. EBITA improvement '25e-'27e adj.
Redeye updates its estimates and valuation following Catella’s Q3 2025 report.
Enea updated its financial targets on 4 November 2025 to achieve an average CAGR of >10% over the...
* We update our model after the announced divestment of Public * Extraordinary dividend on the cards...
QBIM redovisade totala intäkter om 1,9 MSEK (2,3), varav nettoomsättningen uppgick till 0,7 MSEK (1,...
Adtraction redovisade minskad nettoomsättning och ökad EBITA i det tredje kvartalet.
